Prelude Therapeutics has filed a patent for heterocycle CDK inhibitors, which are compounds that can be used in pharmaceutical compositions. The patent also covers methods of using and preparing these inhibitors. GlobalData’s report on Prelude Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Prelude Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Prelude Therapeutics's grant share as of September 2023 was 14%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230265083A1) describes a compound and its pharmaceutically acceptable forms that have potential applications in the treatment of various diseases and disorders associated with aberrant CDK activity. The compound is represented by Formula (I), Formula (II-a), Formula (II-b), Formula (X), or Formula (XI). In particular, the patent claims a compound where X is O and m is 2. The compound can have various substituents, such as R5, R6, R7, and R8, which can be independently H or C1-6 alkyl. Additionally, the compound can have different substituents on R1, R2, R3, R4, and Rb, including cycloalkyl, heterocycloalkyl, and alkyl groups. The patent also includes specific examples of compounds falling within the claimed scope.
The patent further claims pharmaceutical compositions comprising the compound or its pharmaceutically acceptable forms, along with optional excipients. These compositions can have an enantiomeric excess of at least 90%, 95%, 98%, or 99% of one enantiomer of the compound. The compositions can be used to inhibit CDK enzymes, particularly CDK9, which are associated with aberrant CDK activity. Additionally, the patent claims methods of treating diseases or disorders associated with aberrant CDK activity, including colon cancer, breast cancer, lung cancer, bladder cancer, ovarian cancer, prostate cancer, leukemia, lymphoma, myeloma, and pancreatic cancer. The method involves administering the compound or its pharmaceutically acceptable forms to the subject in need.
In summary, the patent describes a compound and its pharmaceutically acceptable forms that have potential applications in inhibiting CDK enzymes and treating diseases or disorders associated with aberrant CDK activity. The compound can be formulated into pharmaceutical compositions with high enantiomeric purity and can be used in the treatment of various cancers and other related conditions.
To know more about GlobalData’s detailed insights on Prelude Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
